Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257438 · ClinicalTrials.gov registry record · NA
FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
A NA study of Restenosis, sponsored by C. R. Bard.
- Completed
- Registry status
- NA
- Development phase
- 275
- Enrollment target
- 20
- Study locations
NCT01257438 is a NA study of Restenosis that has completed, run by C. R. Bard. The registered enrollment target is 275 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT01257438, a NA study of Restenosis, has completed, sponsored by C. R. Bard.
- COMPLETED
- Registry status
- NA
- Development phase
- 275 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to demonstrate that the FLUENCY® PLUS Endovascular Stent Graft can effectively and safely treat in-stent restenotic lesions in the venous outflow of the Arteriovenous (AV) access circuit of hemodialysis patients with either of the two predominant vascular access types - those with an AV graft and those with an AV fistula.
Conditions Studied
Interventions
- DEVICE Fluency Plus Endovascular Stent Graft
- DEVICE Percutaneous Transluminal Angioplasty only
Study Locations (20)
Arizona
- Southwest Kidney Institute Inc - Phoenix
- Arizona Kidney Disease & Hypertension Center-Surgery Center - Phoenix
- Capital Nephrology Access Center - Sacramento
- Angiocare LLC w/Renal Care Associates PC - Tucson
California
- Greater Long Beach Vascular Access Center - Bellflower
- Ladenheim Dialysis Access Centers - Fresno
Connecticut
- American Access Care Connecticut Image Guided Surgery - Fairfield
- Yale University - New Haven
Georgia
- Vascular & Interventional Care Center - Augusta
- Savannah Vascular Surgery - Savannah
Alabama
- University of Alabama Radiology Dept - Birmingham
Florida
- First Coast Cardiovascular Institute - Jacksonville
Illinois
- MakrisMD, LLC, d/b/a Chicago Access Care - Hinsdale
Massachusetts
- The Vascular Access Center - West Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01257438
The ClinicalTrials.gov registry entry for NCT01257438 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is C. R. Bard, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Restenosis appearing as the primary indexed condition, and to 2 interventions - of which Fluency Plus Endovascular Stent Graft is the first listed.
NCT01257438 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT01257438 about?
NCT01257438 is a clinical study titled "FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis". The primary purpose of this study is to demonstrate that the FLUENCY® PLUS Endovascular Stent Graft can effectively and safely treat in-stent restenotic lesions in the venous outflow of the Arteriovenous (AV) access circuit of hemodialysis patients with either of the two predominant vascular access ...
What is the current status of trial NCT01257438?
This trial is currently completed. It is a NA study. The enrollment target is 275 participants. The study started on 2010-12. Estimated completion is 2016-01.
What conditions does trial NCT01257438 study?
This clinical trial studies the following conditions: Restenosis.
What interventions are being tested in trial NCT01257438?
The interventions under investigation include: Fluency Plus Endovascular Stent Graft (DEVICE), Percutaneous Transluminal Angioplasty only (DEVICE).
Who is sponsoring clinical trial NCT01257438?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01257438 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Restenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.